Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 7/2017

19.08.2017 | ORIGINAL ARTICLE

Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm

verfasst von: Joaquín Gómez-Ramírez, Radu Mihai

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

In recent years, there has been increasing interest in understanding the implications of diagnosing normocalcaemic primary hyperparathyroidism (nPHPT). Many patients hope that nPHPT might explain some of their symptoms, but surgeons hesitate to offer treatment to patients whose calcium levels are normal but whose parathyroid hormone (PTH) levels are elevated in the absence of secondary causes of hyperparathyroidism. This potential new diagnosis is not well understood and may lead to inappropriate investigation and possible unnecessary operations. However, because a significant number of patients with nPHPT progress to hypercalcaemic primary hyperparathyroidism (PHPT), some consider nPHPT to be an early or mild form of hypercalcaemia. Rather than being an indolent disease, nPHPT was reported to be associated with systemic complications similar to ‘classical’ PHPT, and hence there is growing interest to understand who should be offered surgical treatment and who should be monitored. Further standardisation of diagnostic definition, associated complications, patient selection, surgical management and long-term outcomes are necessary. The recommendations outlined in this review are based on limited evidence from non-randomised cohort studies and expert opinion.
Literatur
1.
Zurück zum Zitat Sitges-Serra A, Bergenfelz A (2007) Clinical update: sporadic primary hyperparathyroidism. Lancet (London, England) 370(9586):468–470CrossRef Sitges-Serra A, Bergenfelz A (2007) Clinical update: sporadic primary hyperparathyroidism. Lancet (London, England) 370(9586):468–470CrossRef
2.
Zurück zum Zitat Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365(25):2389–2397CrossRefPubMed Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365(25):2389–2397CrossRefPubMed
3.
Zurück zum Zitat Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):351–365CrossRefPubMedPubMedCentral Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):351–365CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Wills MR, Pak CY, Hammond WG, Bartter FC (1969) Normocalcemic primary hyperparathyroidism. Am J Med 47(3):384–391CrossRefPubMed Wills MR, Pak CY, Hammond WG, Bartter FC (1969) Normocalcemic primary hyperparathyroidism. Am J Med 47(3):384–391CrossRefPubMed
5.
Zurück zum Zitat Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42(3):764–766CrossRefPubMed Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42(3):764–766CrossRefPubMed
6.
Zurück zum Zitat Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3):287–294CrossRefPubMed Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3):287–294CrossRefPubMed
7.
Zurück zum Zitat Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F (2011) Normocalcaemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55(5):314–317CrossRefPubMedPubMedCentral Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F (2011) Normocalcaemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55(5):314–317CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98(7):2734–2741CrossRefPubMedPubMedCentral Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98(7):2734–2741CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8):3001–3005CrossRefPubMed Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8):3001–3005CrossRefPubMed
10.
Zurück zum Zitat Tuna MM, Caliskan M, Unal M, Demirci T, Dogan BA, Kucukler K et al (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34(3):331–335CrossRefPubMed Tuna MM, Caliskan M, Unal M, Demirci T, Dogan BA, Kucukler K et al (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34(3):331–335CrossRefPubMed
11.
Zurück zum Zitat Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352CrossRefPubMedPubMedCentral Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98(8):3213–3220CrossRefPubMed Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98(8):3213–3220CrossRefPubMed
13.
Zurück zum Zitat Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A et al (2014) Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 25(7):1963–1968CrossRefPubMed Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A et al (2014) Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 25(7):1963–1968CrossRefPubMed
14.
Zurück zum Zitat Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88(11):5348–5352CrossRefPubMed Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88(11):5348–5352CrossRefPubMed
15.
Zurück zum Zitat Siprova H, Frysak Z, Soucek M (2016) Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract 22(3):294–301CrossRefPubMed Siprova H, Frysak Z, Soucek M (2016) Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract 22(3):294–301CrossRefPubMed
16.
Zurück zum Zitat Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117(11):861–863CrossRefPubMed Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117(11):861–863CrossRefPubMed
17.
Zurück zum Zitat Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, Dogan Cakir S et al (2016) Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J 63(2):111–118CrossRefPubMed Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, Dogan Cakir S et al (2016) Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J 63(2):111–118CrossRefPubMed
18.
Zurück zum Zitat Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100(6):2420–2424CrossRefPubMed Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100(6):2420–2424CrossRefPubMed
20.
Zurück zum Zitat Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569CrossRefPubMedPubMedCentral Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298CrossRefPubMed Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298CrossRefPubMed
22.
Zurück zum Zitat Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648CrossRefPubMed Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648CrossRefPubMed
23.
Zurück zum Zitat Balsa JA, Botella-Carretero JI, Peromingo R, Zamarron I, Arrieta F, Munoz-Malo T et al (2008) Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Investig 31(10):845–850CrossRef Balsa JA, Botella-Carretero JI, Peromingo R, Zamarron I, Arrieta F, Munoz-Malo T et al (2008) Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Investig 31(10):845–850CrossRef
24.
Zurück zum Zitat Selby PL, Davies M, Adams JE, Mawer EB (1999) Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res Off J Am Soc Bone Miner Res 14(4):652–657CrossRef Selby PL, Davies M, Adams JE, Mawer EB (1999) Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res Off J Am Soc Bone Miner Res 14(4):652–657CrossRef
25.
Zurück zum Zitat Lavryk OA, Siperstein AE (2017) Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J Surg 41(1):122–128CrossRefPubMed Lavryk OA, Siperstein AE (2017) Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J Surg 41(1):122–128CrossRefPubMed
26.
Zurück zum Zitat Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–3579CrossRefPubMed Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–3579CrossRefPubMed
27.
Zurück zum Zitat Nordenstrom E, Katzman P, Bergenfelz A (2011) Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 44(10–11):849–852CrossRefPubMed Nordenstrom E, Katzman P, Bergenfelz A (2011) Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 44(10–11):849–852CrossRefPubMed
28.
Zurück zum Zitat Ong GS, Walsh JP, Stuckey BG, Brown SJ, Rossi E, Ng JL et al (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 97(9):3138–3145CrossRefPubMed Ong GS, Walsh JP, Stuckey BG, Brown SJ, Rossi E, Ng JL et al (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 97(9):3138–3145CrossRefPubMed
29.
Zurück zum Zitat Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36(4):761–766CrossRefPubMed Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36(4):761–766CrossRefPubMed
30.
Zurück zum Zitat Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930CrossRefPubMed Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930CrossRefPubMed
31.
Zurück zum Zitat KDIGO (2009) Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–130 KDIGO (2009) Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–130
32.
Zurück zum Zitat Coe FL, Canterbury JM, Firpo JJ, Reiss E (1973) Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 52(1):134–142CrossRefPubMedPubMedCentral Coe FL, Canterbury JM, Firpo JJ, Reiss E (1973) Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest 52(1):134–142CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Souberbielle JC, Cavalier E, Cormier C (2015) How to manage an isolated elevated PTH? Ann Endocrinol 76(2):134–141CrossRef Souberbielle JC, Cavalier E, Cormier C (2015) How to manage an isolated elevated PTH? Ann Endocrinol 76(2):134–141CrossRef
34.
Zurück zum Zitat Carneiro-Pla DM, Irvin GL 3rd, Chen H (2007) Consequences of parathyroidectomy in patients with “mild” sporadic primary hyperparathyroidism. Surgery 142(6):795–799 discussion 9.e1–2CrossRefPubMed Carneiro-Pla DM, Irvin GL 3rd, Chen H (2007) Consequences of parathyroidectomy in patients with “mild” sporadic primary hyperparathyroidism. Surgery 142(6):795–799 discussion 9.e1–2CrossRefPubMed
35.
Zurück zum Zitat Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA et al (2017) Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161(1):70–77CrossRefPubMed Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA et al (2017) Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161(1):70–77CrossRefPubMed
36.
Zurück zum Zitat Goldfarb M, Gondek S, Irvin GL 3rd, Lew JI (2011) Normocalcemic parathormone elevation after successful parathyroidectomy: long-term analysis of parathormone variations over 10 years. Surgery 150(6):1076–1084CrossRefPubMed Goldfarb M, Gondek S, Irvin GL 3rd, Lew JI (2011) Normocalcemic parathormone elevation after successful parathyroidectomy: long-term analysis of parathormone variations over 10 years. Surgery 150(6):1076–1084CrossRefPubMed
37.
Zurück zum Zitat Carsello CB, Yen TW, Wang TS (2012) Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery 152(4):575–581 discussion 81–3CrossRefPubMed Carsello CB, Yen TW, Wang TS (2012) Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery 152(4):575–581 discussion 81–3CrossRefPubMed
38.
Zurück zum Zitat Stuart HC, Harvey A, Pasieka JL (2014) Normocalcemic hyperparathyroidism: preoperatively a disease, postoperatively cured? Am J Surg 207(5):673–680 discussion 80–1CrossRefPubMed Stuart HC, Harvey A, Pasieka JL (2014) Normocalcemic hyperparathyroidism: preoperatively a disease, postoperatively cured? Am J Surg 207(5):673–680 discussion 80–1CrossRefPubMed
Metadaten
Titel
Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm
verfasst von
Joaquín Gómez-Ramírez
Radu Mihai
Publikationsdatum
19.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 7/2017
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1617-2

Weitere Artikel der Ausgabe 7/2017

Langenbeck's Archives of Surgery 7/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.